Beyond Air Financial Results
Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth. The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 while awaiting FDA approval for its second-generation LungFit PH system.
- Term
- Q2 2027
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air